Administration advice :
-Take orally, with or without food
-If a dose is missed, do not double the next dose
Storage requirements :
-Protect from light
-This drug is not an analgesic medication and should not be used to treat pain from other causes.
-For the treatment of gout, the initial response occurs in about 12 to 24 hours; peak response is expected within 48 to 72 hours.
-This drug has a narrow therapeutic window; patients should be monitored for closely for toxicity.
-Monitor for drug toxicity, especially among geriatric and debilitated patients, patients with renal or hepatic impairment, and those with cardiac, renal, hepatic, or gastrointestinal disease.
-Monitor for hematologic toxicities; for patients developing signs or symptoms of blood cell dyscrasias, a full hematologic investigation should be conducted.
-Monitor renal function in patients at-risk for renal impairment
Patient advice :
-Instruct patients on proper use and inform patients that fatal overdose, both accidental and intentional, have occurred; this drug should be kept out of the reach of children.
-Inform patients that there are a number of potentially serious drug interactions; grapefruit, grapefruit juice, and some herbal products should be avoided; patients should check with their healthcare provider before starting any new medications including short-term medications such as antibiotics.
-Inform patients that bone marrow depression and neuromuscular toxicity may occur; patients should seek medical attention promptly for unusual bleeding or bruising, increased infections, weakness or fatigue, muscle pain or weakness, or numbness or tingling in fingers or toes.
-Inform patients that gastrointestinal adverse events occur, but if these events are severe or persistent, they should be reported promptly to their healthcare provider.
Probenecid crosses the placental barrier and appears in cord blood. Colchicine can arrest cell division in animals and plants. In certain species of animals under certain conditions, colchicines has produced teratogenic effects. The possibility of such effects in humans also has been reported. Because of the colchicine component, probenecid and colchicine is contraindicated in pregnant patients. The use of any drug in women of childbearing potential requires that the anticipated benefit be weighed against the possible hazards.
Some of the aforementioned studies 2,6,7,11 have confirmed that corticosteroid treatment
is a risk factor for recurrent pericarditis. A possible
mechanism is by permitting more viral
replication, which would perpetuate pericardial
Physicians may worry that withholding corticosteroids in patients with repeated pericardial inflammation might increase the likelihood of constrictive pericarditis or pericardial tamponade. This is unlikely and has not been reported in clinical studies. 12 In fact, the clinical evolution of recurrent pericarditis is characterized by progressively less severe recurrences, usually without serious complications. 2,13
Accordingly, we recommend that corticosteroids not be used for initial treatment of pericarditis or recurrences unless the patient has had no response to NSAIDs or colchicine or if these drugs are both contraindicated.